...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Best practice & research: Clinical haematology >Why the stagnation in effective therapy for MDS?
【24h】

Why the stagnation in effective therapy for MDS?

机译：为什么在有效治疗MDS方面停滞不前？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The question posed above assumes that we are going nowhere in therapies for myelodysplastic syndromes (MDS) and asks, why? Yet, in recent years novel and effective therapies for MDS indeed have begun to emerge, particularly in patients with lower-risk disease. Beyond this, however, most of the progress has been limited to advances in allogeneic transplantation for higher-risk patients. This discussion will focus first on areas where we have moved beyond "stagnation," including these advances in supportive care for lower-risk patients and in emerging transplant gains. Further, in areas that have not seen the same encouraging advances, suggestions are made on how to move the field forward. The promise for the future lies in finding more creative ways to partner molecular genetics, novel drugs, and novel clinical trial designs. (C) 2016 Published by Elsevier Ltd.
机译：上面提出的问题假设我们在骨髓增生异常综合症（MDS）的治疗中无所作为，并问为什么？然而，近年来，确实已经出现了针对MDS的新颖有效的疗法，特别是在低危疾病患者中。然而，除此之外，大多数进展仅限于高危患者的同种异体移植。讨论将首先集中在我们已经超越“停滞”的领域，包括在为低风险患者提供支持治疗方面取得的进展以及在新出现的移植方面取得的进展。此外，在没有看到同样令人鼓舞的进展的领域，就如何推动该领域提出了建议。未来的希望在于找到更多创新的方法来与分子遗传学，新药和新颖的临床试验设计结合。 （C）2016由Elsevier Ltd.出版

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号